What we do
We are developing first-in-class small molecule therapeutics that treat the underlying pathologies of thrombosis and type 1 diabetes. Based on an understanding of the molecular mechanisms of these diseases, these efforts will lead to new treatment paradigms and better outcomes for patients.
Company News
Veralox Therapeutics Appoints Michael Hanna As Chief Medical Officer
Veralox Therapeutics, a biotechnology company developing first-in-class small molecule therapeutics that treat the underlying pathologies of diseases with significant unmet medical needs, today announced the... Read More
Veralox Therapeutics Announces Closing Of $16.6 Million Series A Financing And Announces New Board Members
Veralox Therapeutics, a biotechnology company developing first-in-class small molecule therapeutics that treat the underlying pathologies of diseases with significant unmet medical needs, today announced the... Read More
Veralox Therapeutics Announces FDA Orphan Drug Designation for VLX-1005
FREDERICK, Md.–(BUSINESS WIRE)–Veralox Therapeutics, a biotechnology company developing first-in-class small molecule therapeutics that treat the underlying pathologies of diseases with significant unmet medical needs, today... Read More
Featured Article
Veralox Therapeutics Appoints Michael Hanna As Chief Medical Officer
Veralox Therapeutics, a biotechnology company developing first-in-class small molecule therapeutics that treat the underlying pathologies of diseases with significant unmet medical needs, today announced the... Read More